News / Press Releases - April 29, 2021

Evaluation of Pharmaceutical Legislation: EUCOPE’s Response

The COVID-19 pandemic has again made the vital importance of the European pharmaceutical sector apparent, and while regulatory simplification is welcomed, broader business incentives should also be considered to address the EU’s competitiveness.

In its response to the EU roadmap/IIA on the “Evaluation and revision of the general pharmaceutical legislation”, EUCOPE puts forward its priorities for a balanced framework strengthening the EU’s ability to attract and promote innovation for the benefit of all patients.

You can find the response here.